Aim: To explore the prevalence of autoimmune gastritis in chronic hepatitis C virus (HCV) patients and the influence of α-interferon (IFN) treatment on autoimmune gastritis. Methods: We performed a prospective study on 189 patients with positive anti-HCV and viral RNA enrolled in a 12-month IFN protocol. We evaluated: a) the baseline prevalence of autoimmune gastritis, b) the impact of IFN treatment on development of biochemical signs of autoimmune gastritis (at 3, 6 and 12 months), c) the evolution after IFN withdrawal (12 months) in terms of anti-gastric-parietal-cell antibodies (APCA), gastrin, anti-thyroid, and anti-non-organ-specific antibodies. Results: APCA positivity and 3-fold gastrin levels were detected in 3 (1.6 %) and 9 (5 %) patients, respectively, at baseline, in 25 (13 %) and 31 (16 %) patients at the end of treatment (both P
Fabbri C., Jaboli F., Giovanelli S., Azzaroli F., Pezzoli A., Accogli E., et al. (2003). Gastric autoimmune disorders in patients with chronic hepatitis C before, during the after interferon-alpha therapy. WORLD JOURNAL OF GASTROENTEROLOGY, 9(7), 1487-1490 [10.3748/wjg.v9.i7.1487].
Gastric autoimmune disorders in patients with chronic hepatitis C before, during the after interferon-alpha therapy
Azzaroli F.;Festi D.;Montagnani M.;Roda E.;Mazzella G.
2003
Abstract
Aim: To explore the prevalence of autoimmune gastritis in chronic hepatitis C virus (HCV) patients and the influence of α-interferon (IFN) treatment on autoimmune gastritis. Methods: We performed a prospective study on 189 patients with positive anti-HCV and viral RNA enrolled in a 12-month IFN protocol. We evaluated: a) the baseline prevalence of autoimmune gastritis, b) the impact of IFN treatment on development of biochemical signs of autoimmune gastritis (at 3, 6 and 12 months), c) the evolution after IFN withdrawal (12 months) in terms of anti-gastric-parietal-cell antibodies (APCA), gastrin, anti-thyroid, and anti-non-organ-specific antibodies. Results: APCA positivity and 3-fold gastrin levels were detected in 3 (1.6 %) and 9 (5 %) patients, respectively, at baseline, in 25 (13 %) and 31 (16 %) patients at the end of treatment (both PI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
